/ERAS
ERAS Stock - Erasca, Inc.
Healthcare|BiotechnologyNASDAQ
$3.45-4.17%
$0.15 (-4.17%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.73
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+44.9%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ERAS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.42 – $3.48
TARGET (TP)$5.00
STOP LOSS$3.17
RISK/REWARD1:5.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.17
52W High$3.80
52W Low$1.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-3,732,000 | $-2,641,000 | $-829,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-179,587,000 | $-141,525,000 | $-247,450,000 | $-124,883,000 | $-109,252,000 |
| Net Income | $-161,650,000 | $-125,042,000 | $-242,805,000 | $-122,764,000 | $-101,660,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.69 | $-0.83 | $-1.99 | $-1.03 | $-0.85 |
Company Overview
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
67%
Hold / Neutral
2
22%
Sell / Underperform
1
11%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$8
Average Target
↑ 117.4% Upside
Now
$2
Low
$8
Average
$15
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 16th 2025 | Stifel | Initiation | Buy | $4 |
| September 3rd 2025 | BofA Securities | Downgrade | Underperform | - |
| August 18th 2025 | Morgan Stanley | Downgrade | Equal Weight | $2 |
| March 26th 2025 | Raymond James | Initiation | Outperform | $5 |
| November 18th 2024 | Jefferies | Initiation | Buy | $6 |
| March 11th 2024 | CapitalOne | Initiation | Overweight | $8 |
| January 5th 2024 | BofA Securities | Downgrade | Neutral | $6← $11 |
| October 11th 2023 | H.C. Wainwright | Initiation | Buy | $10 |
| March 30th 2023 | Mizuho | Initiation | Buy | $9 |
| February 24th 2023 | Goldman | Initiation | Buy | $10 |
| February 3rd 2023 | Morgan Stanley | Upgrade | Overweight | $15 |
Earnings History & Surprises
ERASBeat Rate
67%
Last 18 quarters
Avg Surprise
+0.6%
EPS vs Estimate
Beats / Misses
12/4
2 met exactly
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q1 24
+16.7%
$-0.20vs$-0.24
Q2 24
-9.5%
$-0.23vs$-0.21
Q3 24
-70.6%
$-0.29vs$-0.17
Q4 24
+35.3%
$-0.11vs$-0.17
Q1 25
+8.3%
$-0.11vs$-0.12
Q2 25
+8.3%
$-0.11vs$-0.12
Q3 25
0.0%
$-0.12vs$-0.12
Q4 25
0.0%
$-0.11vs$-0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.11 | $-0.11 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.12 | $-0.12 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.12 | $-0.11 | +8.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.17 | $-0.11 | +35.3% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.17 | $-0.29 | -70.6% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.24 | $-0.20 | +16.7% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.27 | $-0.21 | +22.2% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.30 | $-0.22 | +26.7% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.34 | $-0.30 | +11.8% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.30 | $-0.31 | -3.3% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.31 | $-0.26 | +16.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.32 | $-0.27 | +15.6% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $-0.65 | $-1.20 | -84.6% | ✗ MISS |
Latest News
Mizuho Maintains Outperform on Erasca, Raises Price Target to $5
📈 PositiveBenzinga•Dec 9, 2025, 05:27 PM
Guggenheim Maintains Buy on Erasca, Raises Price Target to $5
📈 PositiveBenzinga•Nov 14, 2025, 02:19 PM
Erasca Q3 EPS $(0.11), Inline
➖ NeutralBenzinga•Nov 12, 2025, 09:04 PM
Erasca Announces The U.S. Patent And Trademark Office Has Issued Patent No. 12,458,647 For Its pan-RAS Molecular Glue ERAS-0015 And Related Compounds
📈 PositiveBenzinga•Nov 6, 2025, 01:17 PM
Stifel Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $4
📈 PositiveBenzinga•Oct 16, 2025, 01:43 PM•Also:
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
📉 NegativeSeeking Alpha•Sep 3, 2025, 07:14 PM
Erasca shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform and cut its price target from $4 to $1.
📉 NegativeBenzinga•Sep 3, 2025, 04:17 PM
B of A Securities Downgrades Erasca to Underperform, Lowers Price Target to $1
📉 NegativeBenzinga•Sep 3, 2025, 12:12 PM
Morgan Stanley Downgrades Erasca to Equal-Weight, Lowers Price Target to $2
📉 NegativeBenzinga•Aug 18, 2025, 11:50 AM
Erasca Narrows Loss 46% in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 02:16 AM
Frequently Asked Questions about ERAS
What is ERAS's current stock price?
Erasca, Inc. (ERAS) is currently trading at $3.45 per share. The stock has moved -4.17% today.
What is the analyst price target for ERAS?
The average analyst price target for ERAS is $5.00, based on 1 analyst.
What sector is Erasca, Inc. in?
Erasca, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ERAS's market cap?
Erasca, Inc. has a market capitalization of $0.98 billion, making it a small-cap company.
Does ERAS pay dividends?
No, Erasca, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
Explore stocks similar to ERAS for comparison